SEC Form 4 · accession 0001012975-18-000455
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Enright
Officer — President and CEO · Director
Period of report
May 21, 2018
Accepted (ET)
May 23, 2018 · 5:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (option to buy)F1 | $0.445 | May 21, 2018 | A | 103,158 | A | — | May 21, 2028 | Common Stock, par value $0.0001 | 103,158 | 103,158 | D |
Explanation of responses
- F1Twenty-five percent of the option becomes vested and exercisable on March 1, 2019, and the aggregate unvested remaining portion will vest and become exercisable in equal monthly installments on the first day of each month over the 36-month period starting April 1, 2019.